TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test Different Doses of BI 456906 in Patients With Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients ≥ 18 years and \< 70 years of age at screening~* Body Mass Index (BMI) ≥ 27 kg/m2 and \<40 kg/m2 at screening~* A minimum absolute body weight of 70 kg at screening and a stable body weight (defined as no more than 5% change) 3 months prior to screening~* HbA1c \<6.5%~* Further inclusion criteria apply~Exclusion Criteria:~* Women who are pregnant, nursing, or who plan to become pregnant while in the trial~* Supine blood pressure (BP) ≥160/100 mmHg at screening~* Major surgery (major according to the investigator's assessment) performed within 12 weeks prior to randomization or planned within 12 months after screening~* Any laboratory value outside the reference range that the investigator considers to be of clinical relevance~* Further exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- BI 456906 (Type: EXPERIMENTAL): None
- Placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of COPD in any field in the pre-index period and 60 days after the index date~* Diagnosis of depression/anxiety in any field and a medication for treating depression/anxiety in the pre-index period and 60 days after the index date~* Index date occurs during identification period~* Patients must be continuously eligible during 1-year pre and 1-year post-index date and be of at least 40 years of age~Exclusion Criteria:~* comorbid conditions (respiratory cancer, cystic fibrosis, fibrosis due to tuberculosis, and bronchiectasis, pneumonociosis, pulmonary fibrosis, pulmonary tuberculosis, sarcoidosis) during the 1 year pre or post-index periods~* No other maintenance medications other than the index medication on or 60 days after the index date

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- COPD patients with comorbid depression/anxiety (Type: None): Patients aged 40 and over with COPD and comorbid depression/anxiety. Managed care enrolees (aged \>40 years) having newly initiated drug therapy with FSC or AC during the identification period (01/01/2004 to 06/30/2008) to treat COPD with a medical or pharmacy claim for depression before and 60 days post index date were the target population. The first fill date of FSC or AC was the index date.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing soliD Tumours.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a histologically or cytologically confirmed malignant solid tumour.~* Progression or recurrence of the tumour radiologically established or confirmed within the 4 weeks prior to inclusion.~* Disease must be considered refractory to any line of conventional therapy or for which no effective conventional treatment exists.~* Age: ≥4 to 21 years of age at study entry~* Life expectancy: at least 8 weeks~* ECOG Performance status ≤ 1 or Lansky-Play Scale ≥ 70%~* Written informed consent of parent/guardian and patient assent~* Wash out of 4 weeks in case of prior chemotherapy, 6 weeks if treatment included nitrosoureas, 2 weeks in case of vincristine alone; 6 weeks in case of prior radiotherapy (except palliative radiotherapy on non measurable lesions).~* Patients must have recovered from the acute toxic effects of all prior therapy before enrolment into the study~* Able to comply with scheduled follow-up and with management of toxicity~* All patients with reproductive potential must practice an effective method of birth control while on study.~* Female patients aged \> 12 years must have a negative pregnancy test within 7 days before study treatment.~* Capable of swallowing oral medication~Exclusion Criteria:~* Pregnant and breast feeding women.~* Uncontrolled intercurrent illness or active infection~* Inability to swallow oral medication.~* Patients on anticonvulsants will be allowed on study

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- traetment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to undergo endoscopy with required biopsy~* Ages 1 through 5 years~* Endoscopically confirmed GERD by positive endoscopic evidence of reflux related esophagitis or positive histologic evidence of esophagitis consistent with GERD Other inclusions apply.~Exclusion Criteria:~* History or presence of upper gastrointestinal anatomic or motor disorders~* Known current or active cow's milk allergy~* Malignancy~* Other exclusions apply.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Arm 1- Low Dose pantoprazole
- 2 (Type: ACTIVE_COMPARATOR): Arm 2- Medium Dose pantoprazole
- 3 (Type: ACTIVE_COMPARATOR): Arm 3- High Dose pantoprazole

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety and Tolerability of Ezetimibe (SCH 58235, MK-0653) With Atovastatin (P02154, MK-0653-017)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has successfully completed the 12-week double-blind, efficacy and safety parent study (P00692).~* If female, has a negative pregnancy test prior to study entry and, if of childbearing potential, agrees to practice an effective barrier method of birth control for the duration of the study and for 30 days after the last statin dose.~* If postmenopausal female receiving hormone therapy, a stable estrogen (ERT), estrogen/progestin (HRT) or raloxifene regimen must be maintained during the study period.~* Is willing to continue to follow their prescribed National Cholesterol Education Program (NCEP) Step 1 diet for the duration of the study.~Exclusion Criteria:~* Has discontinued from the parent study (P00692) prior to study completion.~* Is in a situation, or has any condition which, in the opinion of the investigator may interfere with optimal participation.~* Is a pregnant or lactating female.~* Is human immunodeficiency virus (HIV) positive.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 86 Years
- Healthy Volunteers: t

Study Arms:
- Placebo + Atorvastatin (Type: PLACEBO_COMPARATOR): Participants who received placebo in the parent study (P00692) receive placebo (blinded) + atorvastatin (10 mg/day; open-label) in this study.
- Ezetimibe + Atorvastatin (Type: EXPERIMENTAL): Participants who received ezetimibe + atorvastatin, or atorvastatin alone, in the parent study (P00692) receive ezetimibe (blinded) + atorvastatin (10 mg/day; open-label) in this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed stage I, IE, or non-bulky II or IIE non-Hodgkin's lymphoma of one of the following subtypes: Diffuse large B-cell Mantle cell High grade B-cell, Burkitt's or Burkitt like Anaplastic large cell (B-cell phenotype only) Lymphoma must express CD20 All disease must be encompassable in a single radiation port (including any resected disease) Must have at least 1 of the following adverse prognostic features: Non-bulky stage II or non-bulky stage IIE disease Over 60 years of age Zubrod performance status of 2 Elevated serum LDH A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of indolent or aggressive lymphoma will replace the former terminology of low, intermediate, or high grade lymphoma. However, this protocol uses the former terminology.~PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Zubrod 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No medical contraindications to CHOP chemotherapy or rituximab No prior malignancy within past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix No AIDS or HIV Not pregnant or nursing Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY: Biologic therapy: No prior monoclonal antibody therapy Chemotherapy: No prior chemotherapy for lymphoma Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy for lymphoma Surgery: Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CHOP + Rituximab + RT (Type: EXPERIMENTAL): 3 21-day cycles of CHOP (cyclophosphamide 750 mg/m\^2, doxorubicin 50 mg/m\^2, vincristine 1.4 mg/m\^2, prednisone 100 mg x 5 days) + Rituximab 375 mg/m\^2 (x 2 days for cycle 1, x 3 days for cycles 2-3). RT 4000-5500 cGy given in 25 fractions starting 3 weeks after completion of CHOP + Rituximab.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of colorectal cancer (either newly diagnosed or recurrent disease) with evidence of metastatic disease. (Stage IV distant disease)~* Present or past histological documentation of adenocarcinoma of the colon or rectum. The site of the primary lesion must be or have been confirmed endoscopically, radiologically, or surgically to be or have been in the large bowel. Patients with a history of colorectal cancer treated by surgical resection who develop radiological or clinical evidence of metastatic cancer do not require separate histological or cytological confirmation of metastatic disease unless:~* An interval of greater than five years has elapsed between the primary surgery and the development of metastatic disease.~* The primary cancer was a Duke's A or B1.~* Physicians should consider biopsy of lesions to establish the diagnosis of metastatic colorectal cancer in each case if there is substantial clinical ambiguity regarding the nature of source of apparent metastases.~Exclusion Criteria:~* Patients who received any prior systemic anticancer therapy for metastatic colorectal cancer (e.g., chemotherapy, antibody therapy, immunotherapy, gene therapy, vaccine therapy, cytokine therapy, or other experimental agents).~* Patients cannot have concurrent malignancies at study entry.~* Exceptions: Patients with prior non-colorectal malignancies will be eligible if they have been disease-free for ³ 3 years or are deemed at low risk for recurrence by their treating physician (e.g., early stage prostate cancer, melanoma or bladder cancer). Patients with squamous or basal cell carcinoma of the skin or in situ cervical cancer that have been effectively treated are eligible, even if these were diagnosed within 3 years before randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Modified Bolus 5-FU/LV with Irinotecan (Type: EXPERIMENTAL): None
- FOLFIRI + bevacizumab (Type: EXPERIMENTAL): None
- miFL + bevacizumab (Type: EXPERIMENTAL): None
- Infusional 5-FU/LV with Irinotecan (Type: EXPERIMENTAL): None
- Oral Capecitabine with Irinotecan (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is able and willing to sign the Informed Consent Form.~* Subject undergoes a transrectal prostate biopsy as part of the standard care in the Radboudumc (Nijmegen), Canisius Wilhelmina hospital (Nijmegen) or Catharina hospital (Nijmegen) (because of suspicion of prostate cancer).~Exclusion Criteria:~* Inability to receive ciprofloxacin (e.g. documented history of sensitivity to medicinal products or excipients similar to those found in the antibiotic prophylaxis, relevant history or presence of cardiovascular disorders)~* Inability to receive either co-trimoxazole, fosfomycin and pivmecillinam/augmentin prophylaxis for any reason (e.g. documented history of sensitivity to medicinal products or excipients similar to those found in the antibiotic prophylaxis)~* Inability to understand the nature of the trial and the procedures required.~* Individuals with an urinary tract infection or acute prostatitis within 14 days prior to intervention.~* Individuals who receive antibiotics within 14 days before prostate biopsy.~* Individuals who fail to send a rectum swab to the microbiology laboratory.~* Individuals whose rectal swab shows no growth on a (growth) control MacConkey agar without antibiotics.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Targeted antimicrobial prophylaxis (Type: EXPERIMENTAL): Men whose rectal swabs do not show ciprofloxacin-resistant bacteria will receive ciprofloxacin prior to biopsy (equal to the active comparator arm), and men whose swabs do show ciprofloxacin-resistant bacteria will receive alternative oral antibiotics, based on culture results, in the following order:~* trimethoprim/sulfamethoxazole (SXT) 960 mg orally 2 hours before and 12 hours after prostate biopsy, or~* fosfomycin 3 g orally 2 hours before prostate biopsy, or~* pivmecillinam/augmentin respectively 400 mg and 500/125 mg 2 hours before prostate biopsy followed by 2 days with three divided doses each day after prostate biopsy.
- Routine empirical prophylaxis (Type: ACTIVE_COMPARATOR): Ciprofloxacin 500 mg orally 2 hours before and 12 hours after transrectal prostate biopsy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy and Safety of a Fixed-dose, Single-capsule Budesonide-formoterol Combination in Uncontrolled Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of uncontrolled asthma~* Age ranged from 18 to 77 years~* Nonsmokers~Exclusion Criteria:~* Use of oral corticosteroids, anti-leukotrienes, immunoglobulins, beta blockers, digitalis, amiodarone, antifungals, antidepressants, monoamine oxidase inhibitors and tricyclics during the standardization~* Atrial fibrillation, Flutter, severe and complex tachyarrhythmias atrioventricular block 1,2 and 3~* Diabetes mellitus~* Pregnancy~* Neuropsychiatric diseases~* Pulmonary malformations, tuberculosis, Cystic fibrosis~* Immunosuppressive treatment~* Hospitalization for asthma or respiratory infection in last 30 days~* Severe systemic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- Fixed Combination of Budesonide and formoterol (Type: EXPERIMENTAL): Group 1 (experimental): Fixed Combination of Budesonide and formoterol
- Budesonide (Type: ACTIVE_COMPARATOR): Group 2 (comparator): Budesonide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult male aged 18-45 years.~* Normal medical history and physical examination. Minor physical ailments e.g. Fungal skin infections, will not be sufficient to define a physical examination as abnormal.~* Normal urine dipstick, blood count, liver enzymes, and creatinine~* Frequency \<4 SFU per/well/3x105 PBMC as determined by ELISPOT with ESAT6/CFP-10 antigens and less than 100 SFU per/well/1x106 PBMC as determined by ELISPOT with PPD.~* Mantoux negative (0.0 mm induration).~* Normal Chest X-ray.~* Willing to donate blood samples as required by the protocol~Exclusion Criteria:~* Clinically significant history of skin disorder (eczema, psoriasis, etc.), allergy, immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease or neurological illness.~* Any clinical evidence of immunosuppression such as oral candida, stomatitis, aphthous or septic ulceration, septic skin lesions or any clinical or laboratory evidence of infection or immunocompromise.~* History of splenectomy~* Haematocrit of less than 30%~* Serum creatinine concentration \>130mmol~* Serum ALT concentration \>80IU/L~* Blood transfusion within one month of the beginning of the study~* History of vaccination with any previous experimental poxvirus vaccine~* Administration of any other vaccine or immunoglobulin within two weeks before or two weeks after vaccination.~* Positive HIV antibody test, evidence of HBV (Hepatitis B vaccination is not an exclusion criteria)..~* Current participation in another clinical trial, or within 12 weeks of this study~* Any other finding which in the opinion of the investigators would increase the risk of an adverse outcome from participation in the trial.~* Likelihood of travel away from the study area for the duration of the study~* Untreated malaria infection

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients to undergo surgery for an ovarian cyst~* presumed benign ovarian tumor (according to the rules of the IOTA(International Ovarian Tumor Analysis Group) group)~* agreement to participate in the study~Exclusion Criteria:~* pregnant patient~* minor patient~* Patient under guardianship, trusteeship, or deprived of liberty~* Patient with ascites or metastases or malignant ovarian mass presumed under the rules of IOTA group.~* Patient with an adnexal torsion is suspected~* Patient unable to understand the proposed study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete